Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.
Lévy V, Zohar S, Bardin C, Vekhoff A, Chaoui D, Rio B, Legrand O, Sentenac S, Rousselot P, Raffoux E, Chast F, Chevret S, Marie JP. Lévy V, et al. Among authors: vekhoff a. Br J Cancer. 2006 Aug 7;95(3):253-9. doi: 10.1038/sj.bjc.6603265. Epub 2006 Jul 18. Br J Cancer. 2006. PMID: 16847470 Free PMC article. Clinical Trial.
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.
Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R, Dumontet C, Morariu-Zamfir R, Lambert JM, Ozoux ML, Poncelet P, San Miguel JF, Legrand O, DeAngelo DJ, Giles FJ, Marie JP. Lapusan S, et al. Among authors: vekhoff a. Invest New Drugs. 2012 Jun;30(3):1121-31. doi: 10.1007/s10637-011-9670-0. Epub 2011 Apr 26. Invest New Drugs. 2012. PMID: 21519855 Clinical Trial.
Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A, Ahmed SO, Rasheed W, Shaheen M, Belhocine R, Brissot E, Dulery R, Eder S, Giannotti F, Isnard F, Lapusan S, Rubio MT, Vekhoff A, Aljurf M, Legrand O, Mohty M, Bazarbachi A. Battipaglia G, et al. Among authors: vekhoff a. Cancer. 2017 Aug 1;123(15):2867-2874. doi: 10.1002/cncr.30680. Epub 2017 Apr 7. Cancer. 2017. PMID: 28387928 Free article.
Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.
Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P; European Acute Promyelocytic Leukemia Group. Adès L, et al. Among authors: vekhoff a. J Clin Oncol. 2006 Dec 20;24(36):5703-10. doi: 10.1200/JCO.2006.08.1596. Epub 2006 Nov 20. J Clin Oncol. 2006. PMID: 17116939 Clinical Trial.
Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia.
Genthon A, Dragoi D, Memoli M, Hirsch P, Favale F, Suner L, Chaquin M, Boncoeur P, Marjanovic Z, Bonnin A, Sestili S, Dulery R, Malard F, Brissot E, Banet A, van de Wyngaert Z, Vekhoff A, Delhommeau F, Mohty M, Legrand O. Genthon A, et al. Among authors: vekhoff a. Br J Haematol. 2022 Aug;198(4):780-784. doi: 10.1111/bjh.18290. Epub 2022 May 26. Br J Haematol. 2022. PMID: 35615877 No abstract available.
72 results